FDA approves pralsetinib for RET-altered thyroid cancers
On December 1, 2020, the Food and Drug Administration approved pralsetinib for adult and paediatric…
Browsing: pralsetinib
FDA approves pralsetinib for lung cancer with RET gene fusions
The Food and Drug Administration granted accelerated approval to pralsetinib for adult patients with metastatic…
ASCO 2020: Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene fusions
The targeted therapy pralsetinib appears to have high response rates and durable activity in patients…